PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 103 filers reported holding PUMA BIOTECHNOLOGY INC in Q4 2021. The put-call ratio across all filers is 0.85 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,261,248 | -17.0% | 479,511 | +11.4% | 0.00% | – |
| Q2 2023 | $1,518,987 | +8.5% | 430,308 | -5.0% | 0.00% | – |
| Q1 2023 | $1,400,095 | +142041.6% | 453,105 | +94.7% | 0.00% | – |
| Q4 2022 | $985 | -99.3% | 232,769 | +306.2% | 0.00% | – |
| Q3 2022 | $136,000 | -54.2% | 57,305 | +35.5% | 0.00% | – |
| Q3 2021 | $297,000 | +0.3% | 42,298 | +31.0% | 0.00% | – |
| Q2 2021 | $296,000 | -25.4% | 32,281 | +704.2% | 0.00% | – |
| Q4 2017 | $397,000 | -91.4% | 4,014 | -89.6% | 0.00% | -100.0% |
| Q3 2017 | $4,615,000 | +26.3% | 38,550 | +23.2% | 0.00% | 0.0% |
| Q2 2015 | $3,654,000 | -47.5% | 31,299 | +6.2% | 0.00% | -50.0% |
| Q1 2015 | $6,956,000 | +59.4% | 29,462 | +27.8% | 0.00% | +33.3% |
| Q4 2014 | $4,364,000 | +196.1% | 23,059 | +273.1% | 0.00% | +200.0% |
| Q3 2014 | $1,474,000 | +85.4% | 6,180 | -18.7% | 0.00% | 0.0% |
| Q1 2014 | $795,000 | – | 7,606 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Athyrium Capital Management, LP | 1,792,114 | $4,713,260 | 4.15% |
| Eversept Partners, LP | 1,681,149 | $4,421,422 | 0.37% |
| Camber Capital Management LP | 4,235,000 | $11,138 | 0.37% |
| Kynam Capital Management, LP | 473,975 | $1,246,554 | 0.20% |
| GLOBEFLEX CAPITAL L P | 538,559 | $1,416,410 | 0.17% |
| Affinity Asset Advisors, LLC | 202,349 | $532,178 | 0.15% |
| GSA CAPITAL PARTNERS LLP | 279,629 | $735 | 0.06% |
| RICE HALL JAMES & ASSOCIATES, LLC | 363,666 | $956,442 | 0.06% |
| Patriot Financial Group Insurance Agency, LLC | 67,000 | $176,210 | 0.04% |
| ACADIAN ASSET MANAGEMENT LLC | 1,858,000 | $4,884 | 0.02% |